WOMAN Trial Collaborators. (2017). "Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial." The Lancet , 389(10084), 2105–2116.
The trial found that TXA significantly reduced death due to bleeding.
The WOMAN Trial concluded that:
Postpartum hemorrhage (PPH) is the leading cause of maternal mortality globally, responsible for approximately 100,000 deaths annually. Tranexamic acid is an antifibrinolytic agent that inhibits the breakdown of blood clots (fibrinolysis). While it was known to reduce bleeding in surgery and trauma, its specific role in childbirth—particularly regarding safety and survival rates—required robust clinical evidence.
Following the trial's success, the WHO recommended TXA as a first-line PPH treatment, advocating for slow IV administration as soon as possible, with potential for a second dose if bleeding continues. woman trial txa
There are two major contexts in which "Woman Trial TXA" is a prominent search topic: and Heavy Menstrual Bleeding . The most famous and impactful study is the WOMAN Trial (World Maternal Antifibrinolytic Trial).
The trial confirmed that time is a critical factor: WOMAN Trial Collaborators
The WOMAN trial demonstrated that tranexamic acid is a safe and effective treatment for post-partum haemorrhage. When given early, National Institutes of Health (.gov)
This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes. Learn more The trial found that TXA significantly reduced death